Immunome, Inc. (IMNM)
23.42
-0.53
(-2.21%)
USD |
NASDAQ |
Sep 16, 16:00
23.42
0.00 (0.00%)
After-Hours: 20:00
Immunome Enterprise Value : 2.198B for Sept. 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 2.198B |
| September 14, 2026 | 2.266B |
| September 11, 2026 | 2.280B |
| September 10, 2026 | 2.314B |
| September 09, 2026 | 2.444B |
| September 08, 2026 | 2.522B |
| September 04, 2026 | 2.517B |
| September 03, 2026 | 2.562B |
| September 02, 2026 | 2.581B |
| September 01, 2026 | 2.551B |
| August 31, 2026 | 2.590B |
| August 28, 2026 | 2.608B |
| August 27, 2026 | 2.756B |
| August 26, 2026 | 2.742B |
| August 25, 2026 | 2.814B |
| August 24, 2026 | 2.658B |
| August 21, 2026 | 2.716B |
| August 20, 2026 | 2.666B |
| August 19, 2026 | 2.864B |
| August 18, 2026 | 2.607B |
| August 17, 2026 | 2.589B |
| August 14, 2026 | 2.567B |
| August 13, 2026 | 2.478B |
| August 12, 2026 | 2.656B |
| August 11, 2026 | 2.459B |
| Date | Value |
|---|---|
| August 10, 2026 | 2.395B |
| August 07, 2026 | 2.320B |
| August 06, 2026 | 2.410B |
| August 05, 2026 | 2.376B |
| August 04, 2026 | 2.324B |
| August 03, 2026 | 2.091B |
| July 31, 2026 | 2.063B |
| July 30, 2026 | 2.099B |
| July 29, 2026 | 2.103B |
| July 28, 2026 | 2.115B |
| July 27, 2026 | 2.043B |
| July 24, 2026 | 2.001B |
| July 23, 2026 | 1.978B |
| July 22, 2026 | 2.077B |
| July 21, 2026 | 2.065B |
| July 20, 2026 | 1.995B |
| July 17, 2026 | 2.013B |
| July 16, 2026 | 2.000B |
| July 15, 2026 | 2.081B |
| July 14, 2026 | 2.044B |
| July 13, 2026 | 2.068B |
| July 10, 2026 | 2.130B |
| July 09, 2026 | 2.223B |
| July 08, 2026 | 2.205B |
| July 07, 2026 | 2.248B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 9.749B |
| Oncolytics Biotech, Inc. | 93.55M |
| Sangamo Therapeutics, Inc. | 52.77M |
| Sarepta Therapeutics, Inc. | 2.446B |
| Anixa Biosciences, Inc. | 78.07M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -73.13M |
| Total Expenses (Quarterly) | 73.13M |
| EPS Diluted (Quarterly) | -0.6456 |
| Earnings Yield | -10.79% |
| Normalized Earnings Yield | -10.47 |